Fingerprint
Dive into the research topics of 'Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
Ursula Matulonis, Ignace Vergote, Floor Backes, Lainie P. Martin, Scott McMeekin, Michael Birrer, Frank Campana, Yi Xu, Coumaran Egile, Sharad A Ghamande
Research output: Contribution to journal › Article › peer-review
90
Scopus
citations